The human glutathione S-transferases: comparison of isoenzyme expression in normal and astrocytoma brain

• Published in: Biochimica et biophysica acta Vol. 1139; no. 3; pp. 222 - 228
• Main Authors: Strange, R C, Fryer, A A, Matharoo, B, Zhao, L, Broome, J, Campbell, D A, Jones, P, Pastor, I C, Singh, R V
• Format: Journal Article
• Language: English
• Published: Netherlands 07.07.1992
• Subjects: Astrocytoma - enzymology; Brain - enzymology; Brain Neoplasms - enzymology; Cytosol - enzymology; Glioma - enzymology; Glutathione Transferase - classification; Glutathione Transferase - metabolism; Humans; Isoenzymes - metabolism; Liver - enzymology
• ISSN: 0006-3002
• DOI: 10.1016/0925-4439(92)90138-D

We describe expression of alpha, mu and pi class glutathione S-transferases (GST) in brain tissue from 21 controls and uninfiltrated and tumour tissue from 17 glioma patients. GST were sequentially resolved by chromatofocusing into the GST2, GST1, GST5, GST2 (5.5), GST3, GST6 sets and the contribution of each to total activity determined. The immunological identity of these isoforms was studied using immunoblotting. The pi class GST3 isoform was the major contributor to activity in control tissue (70.9%) and, uninfiltrated (75.1%) and tumour samples (82.4%). Expression was significantly greater in the tumours (P less than 0.05). Expression of alpha isoforms GST2 and GST2 (5.5) was variable with most subjects demonstrating no detectable GST2 (B1 and B2 chromatofocused monomers). An isoform termed GST2 (5.5) chromatofocussed at pH 5.5 and cross-reacted with antisera to B1. It was detected in most control and glioma patients and comprised about 5% of total activity. The contribution of GST2 and GST2 (5.5) to activity was similar in control, uninfiltrated and tumour tissue. Two mu class enzymes, GST1 and GST5, were identified. GST1 isoforms were detected in 9 of 21 control samples, the phenotype of these and matched liver samples were identical. GST1 isoforms were detected in 4 of 16 tumour samples, a significantly lower incidence than in a previously established control group. GST5 was expressed in most samples, the contribution of this locus to activity was significantly reduced in the tumours (5.2%) compared with control samples (14.5%).